临床肝胆病杂志2024，Vol.40Issue(12)：2524-2530,7.DOI:10.12449/JCH241225
肝细胞癌仑伐替尼耐药的分子机制
Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma
摘要
Abstract
Hepatocellular carcinoma is the most common malignancy of the liver and poses serious health burdens on China and the whole world.However,most patients with hepatocellular carcinoma are already in the advanced stage at the time of diagnosis,with fewer opportunities for surgery and limited treatment options.In recent years,the advances in molecular targeted therapies have brought new hope for patients with advanced hepatocellular carcinoma.Among these therapies,lenvatinib is the second first-line drug after sorafenib approved by the US Food and Drug Administration for the treatment of advanced hepatocellular carcinoma,and it has attracted widespread attention for its powerful anti-tumor properties.However,the efficacy of lenvatinib is severely limited by its drug resistance.This article reviews the research advances in the molecular mechanisms of lenvatinib resistance in hepatocellular carcinoma and discusses possible ways to improve the efficacy of lenvatinib,so as to improve its efficacy.关键词
癌,肝细胞/仑伐替尼/抗药性,肿瘤Key words
Carcinoma,Hepatocellular/Lenvatinib/Drug Resistance,Neoplasm引用本文复制引用
姚晓萌,孙可可,林云凯,汪慧,董立巍,陈磊,胡和平..肝细胞癌仑伐替尼耐药的分子机制[J].临床肝胆病杂志,2024,40(12):2524-2530,7.基金项目
国家重大科学仪器设备开发专项(2012YQ220113) National Major Scientific Instrument and Equipment Development Project(2012YQ220113) （2012YQ220113）
